Travere Plans To Submit sNDA To FDA In Q1 2024 For Conversion Of Existing US Accelerated Approval Of FILSPARI (Sparsentan) In IgAN To Full Approval
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics plans to submit a supplemental New Drug Application (sNDA) to the FDA in Q1 2024 for the conversion of the existing US accelerated approval of FILSPARI (Sparsentan) in IgA nephropathy (IgAN) to full approval.
December 04, 2023 | 9:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Travere Therapeutics' announcement of its intention to submit an sNDA for FILSPARI in IgAN to the FDA for full approval could positively influence investor sentiment and potentially increase the stock's value in the short term.
The submission of an sNDA for full FDA approval is a significant regulatory milestone that can lead to increased market confidence in Travere Therapeutics' product, FILSPARI. If investors perceive this news as a step towards greater market potential and revenue growth for FILSPARI, it could result in a positive short-term impact on TVTX's stock price. However, the actual impact will depend on market perception, the current progress of the drug, and the competitive landscape.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100